[23] In the diseased brain, GLP-1 receptor agonist treatment is associated with protection against a range of experimental disease models such as Parkinson's disease, [24] [18] Alzheimer's disease, [25] [26] stroke, [24] traumatic brain injury, [14] [19] and multiple sclerosis
Neuropharmacology 25 , 125131 (1986)
Medications originally developed to manage type 2 diabetes and obesity are now the subject of rigorous clinical trials investigating their potential to treat addiction and the early results are generating serious optimism among researchers and clinicians alike
But it works and it is the right tool for you are two very different questions
Patients focused on training recovery may also review strength and performance support
Having accurate numbers allows you to make informed decisions about whether to continue therapy, reduce doses, or explore alternative approaches